Pathologic findings at risk-reducing salpingo-oophorectomy

Primary results from Gynecologic Oncology Group trial GOG-0199

Mark E. Sherman, Marion Piedmonte, Phuong L. Mai, Olga B. Ioffe, Brigitte Maria Ronnett, Linda Van Le, Iouri Ivanov, Maria C. Bell, Stephanie V. Blank, Paul Disilvestro, Chad A. Hamilton, Krishnansu S. Tewari, Katie Wakeley, Noah D. Kauff, S. Diane Yamada, Gustavo Rodriguez, Steven J. Skates, David S. Alberts, Joan L. Walker, Lori Minasian & 2 others Karen Lu, Mark H. Greene

Research output: Contribution to journalArticle

Abstract

Purpose: Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study.

Participants and Methods: This analysis included asymptomatic high-risk women age ≥ 30 years who elected RRSO at enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125 (CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed according to a standardized tissue processing protocol and underwent central pathology panel review. Research-based BRCA1/2 mutation testing was performed when a participant's mutation status was unknown at enrollment. Relationships between participant characteristics and diagnostic findings were assessed using univariable statistics and multivariable logistic regression.

Results: Invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966 RRSOs (BRCA1 mutation carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P.001) were associated with detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2 mutation testing and normal CA-125 levels, findings at RRSO were benign.

Conclusion: Clinically occult cancer was detected among 2.6% of high-risk women undergoing RRSO BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer.

Original languageEnglish (US)
Pages (from-to)3275-3283
Number of pages9
JournalJournal of Clinical Oncology
Volume32
Issue number29
DOIs
StatePublished - Oct 10 2014

Fingerprint

Ovariectomy
Mutation
Neoplasms
Ovarian Neoplasms
Antigens
Peritoneal Neoplasms
Uncertainty
Logistic Models
Pathology
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Pathologic findings at risk-reducing salpingo-oophorectomy : Primary results from Gynecologic Oncology Group trial GOG-0199. / Sherman, Mark E.; Piedmonte, Marion; Mai, Phuong L.; Ioffe, Olga B.; Ronnett, Brigitte Maria; Van Le, Linda; Ivanov, Iouri; Bell, Maria C.; Blank, Stephanie V.; Disilvestro, Paul; Hamilton, Chad A.; Tewari, Krishnansu S.; Wakeley, Katie; Kauff, Noah D.; Yamada, S. Diane; Rodriguez, Gustavo; Skates, Steven J.; Alberts, David S.; Walker, Joan L.; Minasian, Lori; Lu, Karen; Greene, Mark H.

In: Journal of Clinical Oncology, Vol. 32, No. 29, 10.10.2014, p. 3275-3283.

Research output: Contribution to journalArticle

Sherman, ME, Piedmonte, M, Mai, PL, Ioffe, OB, Ronnett, BM, Van Le, L, Ivanov, I, Bell, MC, Blank, SV, Disilvestro, P, Hamilton, CA, Tewari, KS, Wakeley, K, Kauff, ND, Yamada, SD, Rodriguez, G, Skates, SJ, Alberts, DS, Walker, JL, Minasian, L, Lu, K & Greene, MH 2014, 'Pathologic findings at risk-reducing salpingo-oophorectomy: Primary results from Gynecologic Oncology Group trial GOG-0199', Journal of Clinical Oncology, vol. 32, no. 29, pp. 3275-3283. https://doi.org/10.1200/JCO.2013.54.1987
Sherman, Mark E. ; Piedmonte, Marion ; Mai, Phuong L. ; Ioffe, Olga B. ; Ronnett, Brigitte Maria ; Van Le, Linda ; Ivanov, Iouri ; Bell, Maria C. ; Blank, Stephanie V. ; Disilvestro, Paul ; Hamilton, Chad A. ; Tewari, Krishnansu S. ; Wakeley, Katie ; Kauff, Noah D. ; Yamada, S. Diane ; Rodriguez, Gustavo ; Skates, Steven J. ; Alberts, David S. ; Walker, Joan L. ; Minasian, Lori ; Lu, Karen ; Greene, Mark H. / Pathologic findings at risk-reducing salpingo-oophorectomy : Primary results from Gynecologic Oncology Group trial GOG-0199. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 29. pp. 3275-3283.
@article{2454592113cc4227bb1f2aebd0d4d10a,
title = "Pathologic findings at risk-reducing salpingo-oophorectomy: Primary results from Gynecologic Oncology Group trial GOG-0199",
abstract = "Purpose: Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study.Participants and Methods: This analysis included asymptomatic high-risk women age ≥ 30 years who elected RRSO at enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125 (CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed according to a standardized tissue processing protocol and underwent central pathology panel review. Research-based BRCA1/2 mutation testing was performed when a participant's mutation status was unknown at enrollment. Relationships between participant characteristics and diagnostic findings were assessed using univariable statistics and multivariable logistic regression.Results: Invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6{\%}) of 966 RRSOs (BRCA1 mutation carriers, 4.6{\%}; BRCA2 carriers, 3.5{\%}; and noncarriers, 0.5{\%}; P.001) were associated with detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2 mutation testing and normal CA-125 levels, findings at RRSO were benign.Conclusion: Clinically occult cancer was detected among 2.6{\%} of high-risk women undergoing RRSO BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer.",
author = "Sherman, {Mark E.} and Marion Piedmonte and Mai, {Phuong L.} and Ioffe, {Olga B.} and Ronnett, {Brigitte Maria} and {Van Le}, Linda and Iouri Ivanov and Bell, {Maria C.} and Blank, {Stephanie V.} and Paul Disilvestro and Hamilton, {Chad A.} and Tewari, {Krishnansu S.} and Katie Wakeley and Kauff, {Noah D.} and Yamada, {S. Diane} and Gustavo Rodriguez and Skates, {Steven J.} and Alberts, {David S.} and Walker, {Joan L.} and Lori Minasian and Karen Lu and Greene, {Mark H.}",
year = "2014",
month = "10",
day = "10",
doi = "10.1200/JCO.2013.54.1987",
language = "English (US)",
volume = "32",
pages = "3275--3283",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "29",

}

TY - JOUR

T1 - Pathologic findings at risk-reducing salpingo-oophorectomy

T2 - Primary results from Gynecologic Oncology Group trial GOG-0199

AU - Sherman, Mark E.

AU - Piedmonte, Marion

AU - Mai, Phuong L.

AU - Ioffe, Olga B.

AU - Ronnett, Brigitte Maria

AU - Van Le, Linda

AU - Ivanov, Iouri

AU - Bell, Maria C.

AU - Blank, Stephanie V.

AU - Disilvestro, Paul

AU - Hamilton, Chad A.

AU - Tewari, Krishnansu S.

AU - Wakeley, Katie

AU - Kauff, Noah D.

AU - Yamada, S. Diane

AU - Rodriguez, Gustavo

AU - Skates, Steven J.

AU - Alberts, David S.

AU - Walker, Joan L.

AU - Minasian, Lori

AU - Lu, Karen

AU - Greene, Mark H.

PY - 2014/10/10

Y1 - 2014/10/10

N2 - Purpose: Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study.Participants and Methods: This analysis included asymptomatic high-risk women age ≥ 30 years who elected RRSO at enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125 (CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed according to a standardized tissue processing protocol and underwent central pathology panel review. Research-based BRCA1/2 mutation testing was performed when a participant's mutation status was unknown at enrollment. Relationships between participant characteristics and diagnostic findings were assessed using univariable statistics and multivariable logistic regression.Results: Invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966 RRSOs (BRCA1 mutation carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P.001) were associated with detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2 mutation testing and normal CA-125 levels, findings at RRSO were benign.Conclusion: Clinically occult cancer was detected among 2.6% of high-risk women undergoing RRSO BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer.

AB - Purpose: Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study.Participants and Methods: This analysis included asymptomatic high-risk women age ≥ 30 years who elected RRSO at enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125 (CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed according to a standardized tissue processing protocol and underwent central pathology panel review. Research-based BRCA1/2 mutation testing was performed when a participant's mutation status was unknown at enrollment. Relationships between participant characteristics and diagnostic findings were assessed using univariable statistics and multivariable logistic regression.Results: Invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966 RRSOs (BRCA1 mutation carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P.001) were associated with detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2 mutation testing and normal CA-125 levels, findings at RRSO were benign.Conclusion: Clinically occult cancer was detected among 2.6% of high-risk women undergoing RRSO BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer.

UR - http://www.scopus.com/inward/record.url?scp=84907484183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907484183&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.54.1987

DO - 10.1200/JCO.2013.54.1987

M3 - Article

VL - 32

SP - 3275

EP - 3283

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 29

ER -